Dare Bioscience, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Dare Bioscience, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $2.81M | Mar 28, 2024 |
| FY2023 | Dec 31, 2022 | $10.00M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
| FY2016 | Dec 31, 2016 | $766.0K | Jun 13, 2017 |
| FY2016 | Dec 31, 2014 | $80.0K | Jun 13, 2017 |
| FY2015 | Jun 30, 2014 | $33.0K | Mar 10, 2016 |
| FY2015 | Mar 31, 2014 | $47.0K | Mar 10, 2016 |
| FY2014 | Dec 31, 2013 | $6.0K | Mar 19, 2015 |
| FY2014 | Dec 31, 2012 | $625.0K | Mar 19, 2015 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.03M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.8K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $2.81M | Mar 31, 2025 |
| FY2022 | Dec 31, 2022 | $10.00M | Mar 30, 2023 |
| FY2022 | Dec 31, 2021 | $0 | Mar 30, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.40M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($4.05M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($30.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($30.95M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($38.70M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($27.40M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($14.26M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($16.74M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($11.50M) | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | ($4.95M) | Jun 13, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.55M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($23.45M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($30.94M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($31.39M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($39.07M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($27.40M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($14.34M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($16.88M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($11.18M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($630.6K) | Mar 28, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.52M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $14.31M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $21.54M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $30.04M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $30.62M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $20.77M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $8.55M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.41M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $984.7K | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $3.18M | Jun 13, 2017 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.76M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $9.16M | Mar 26, 2026 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.89M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.47M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($38.86M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($18.09M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($28.76M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($25.23M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($13.32M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($10.27M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($2.54M) | Apr 1, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $385.3K | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $573.0K | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $629.4K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $63.1K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $14.5K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $17.6K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $0 | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $11.8K | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 1, 2019 |
| FY2016 | Dec 31, 2016 | $535.0K | Jun 13, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.47M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $22.10M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $21.28M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $43.83M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $55.81M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $7.55M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.44M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $7.83M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $14.26M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $44.6K | Mar 28, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.63M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $28.11M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $26.33M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $32.71M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $17.05M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $8.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $7.00M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.10M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $967.0K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $755.2K | Mar 28, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.84M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($6.01M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2023 | ($5.05M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2022 | $11.11M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $38.75M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | ($1.15M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $440.8K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $6.73M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $13.29M | Mar 27, 2020 |
| FY2018 | Dec 31, 2016 | ($710.6K) | Apr 1, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $0 | Apr 1, 2019 |
| FY2018 | Dec 31, 2017 | $5.19M | Apr 1, 2019 |
| FY2018 | Jul 19, 2017 | $12.70M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($188.69M) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | ($175.29M) | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | ($171.24M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($141.07M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($110.13M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($71.43M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($44.02M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($28.97M) | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | ($12.23M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | ($727.8K) | Mar 28, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.71M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.70M | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | $10.48M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $34.67M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $51.67M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $4.67M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.78M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $6.81M | Mar 27, 2020 |
| FY2018 | Dec 31, 2017 | $7.56M | Apr 1, 2019 |
| FY2018 | Dec 31, 2016 | $44.6K | Apr 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 26, 2026 |
| FY2024 | Dec 31, 2023 | (4) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 14.50M | Mar 26, 2026 |
| FY2025 | Dec 31, 2024 | 8.70M | Mar 26, 2026 |
| FY2024 | Jul 2, 2024 | 8.50M | Mar 31, 2025 |
| FY2024 | Jul 1, 2024 | 101.10M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | 8.33M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 84.83M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 83.94M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 41.60M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 19.68M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 11.42M | Mar 27, 2020 |